A randomized, double-blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 3 fixed doses (50mg Eq [equivalent], 100mg Eq and 150mg Eq) of paliperidone palmitate in subjects with schizophrenia.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 3 fixed doses (50mg Eq [equivalent], 100mg Eq and 150mg Eq) of paliperidone palmitate in subjects with schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2010

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Apr 2010 Results published in International Clinical Psychopharmacology.
    • 17 Dec 2009 Actual patient number changed from 11 to 366 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual patient number changed from 11 to 366 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top